Gut check: Seres Therapeutics shares plunge 75% after microbiome drug fails in trial
July 29, 2016 at 10:39 AM EDT
Shares of Seres Therapeutics plummeted more than 76 percent after its drug for preventing a bacterial infection of the large intestine failed.
